Business Monitor International


Greece Pharmaceuticals & Healthcare Report

Published 10 October 2014

  • 104 pages
  • Instant access to your report online and PDF format through your account library
  • Includes 3 free updated quarterly reports
 
$1,295.00
Greece Pharmaceuticals & Healthcare Report

BMI View:   The pharmaceutical and healthcare industry in Greece will continue to contract over the remainder of 2014. The government will seek to reduce public spending on healthcare , despite both the political and economic situation hav ing stabilised. T he generic drug sector and private healthcare industry may present some growth opportunities in the country.

Headline Expenditure Projections

  • Pharmaceuticals: EUR5.64bn (USD7.45bn) in 2013 to EUR5.28bn (USD7.07bn) in 2014; -6.5% in local currency terms and -5.1% in US dollar terms. Forecast revised upwards from Q 3 14.

  • Healthcare: EUR15.17bn (USD20.02bn) in 2013 to EUR14.35bn (USD19.23bn) in 2014; -5.4% in local currency terms and -3.9% in US dollar terms. Forecast upgraded from previous quarter due to revised historical data.

Risk/Reward Rating: In BMI's Q4 2014 Pharmaceutical Risk/Reward Ratings (RRRs), Greece is ranked third out of the 20 markets in the matrix, scoring 57.8 out of 100. Out of the 20 countries in our ratings, Greece comes behind Poland, but ahead of Russia. Although Greece's financial outlook has stabilised and debts are being paid down, the spectre of further price cuts, clawback taxes and the EOPYY's inability to pay drugmakers in a timely manner present significant risks to the industry.

Key Trends And Developments

August 2014

New cuts to the Greek healthcare service have increased medical costs in the country. Subsequently, the country's lenders have sent an ultimatum to the health ministry to reduce costs, including medical examination and hospitalisation costs, and have urged the creation of a new pay system in hospitals. Under the new system, medical invoices will be tailored to the disease and not the patient. The new system will become effective in 2015.

Pharmaceutical companies in Greece will pay around EUR150mn (USD200.77mn) to the Greek government in the form of clawback during H214.  The distribution of amounts to be paid by the pharmaceutical companies...

Table of Contents

BMI Industry View
7
SWOT
10
Political
12
Economic
13
Business Environment
14
Industry Forecast
15
Pharmaceutical Market Forecast
15
Table: Pharmaceutical Sales, Historical Data And Forecasts (Greece 2010-2018)
17
Healthcare Market Forecast
18
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2010-2018)
19
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2010-2018)
20
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Greece 2010-2018)
20
Prescription Drug Market Forecast
21
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Greece 2010-2018)
22
Patented Drug Market Forecast
23
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Greece 2010-2018)
24
Generic Drug Market Forecast
25
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Greece 2010-2018)
27
OTC Medicine Market Forecast
27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Greece 2010-2018)
29
Table: OTC Medicine Sales Breakdown, 2007-2010
29
Pharmaceutical Trade Forecast
30
Table: Pharmaceutical Trade Data And Forecasts (Greece 2012-2018)
31
Table: Pharmaceutical Trade Data And Forecasts local currency (Greece 2012-2018)
32
Key Risks To BMI's Forecast Scenario
32
Macroeconomic Forecasts
34
Economic Analysis
34
Table: Greece - Economic Activity
38
Industry Risk Reward Ratings
39
Central And Eastern Europe Risk/Reward Ratings
39
Greece Risk/Reward Ratings
46
Rewards
46
Risks
47
Market Overview
48
Industry Trends And Developments
51
Epidemiology
51
Healthcare Sector
53
Healthcare Sector Developments
56
Healthcare Insurance
62
Healthcare Infrastructure
63
Table: Inpatient Facilities And Beds By Speciality, 2008
64
Table: Outpatient Facilities And Beds By Region, 2008
65
Research And Development
66
Clinical Trials
67
Regulatory Development
68
Intellectual Property Regime
69
Pricing Regime
70
Reimbursement Regime
75
Competitive Landscape
78
Company Activity
79
Government Activity
80
Parallel Pharmaceutical Exports
81
Pharmaceutical Retail Sector
81
Table: Pharmacies By Region, 2007-2009
83
Company Profile
84
Alapis Pharma
84
Elpen
86
Genesis Pharma
88
Kleva
90
Lavipharm
91
Pharmathen
93
Vianex
95
Abbott Laboratories
97
GlaxoSmithKline
99
Merck Sharp & Dohme
101
Novartis
103
Sanofi
105
Pfizer
107
Demographic Forecast
109
Table: Greece's Population By Age Group, 1990-2020 ('000)
110
Table: Greece's Population By Age Group, 1990-2020 (% of total)
111
Table: Greece's Key Population Ratios, 1990-2020
112
Table: Greece's Rural And Urban Population, 1990-2020
112
Glossary
113
Methodology
115
Pharmaceutical Expenditure Forecast Model
115
Healthcare Expenditure Forecast Model
115
Notes On Methodology
116
Risk/Reward Ratings Methodology
117
Ratings Overview
118
Table: Pharmaceutical Risk/Reward Ratings Indicators
118
Indicator Weightings
119

The Greece Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Greece Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Greek pharmaceutical and healthcare industry.

Key Benefits

  • Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Greece to test other views - a key input for successful budgeting and strategic business planning in the Greek pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Greek pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Greece.
  • Assess the activities, strategy and market position of your competitors, partners and clients via our Company Profiles (inc. SWOTs, KPIs and latest activity) and Competitive Landscape Tables.

Coverage

BMI Industry View & Industry SWOT

An at-a-glance perspective on latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The SWOT outlines strategic factors which affect BMI's forecast analysis, and taken together with BMI's political, economic and business environment SWOTS, it gives a complete overview of market climate.

Market Summary

Snapshot of key market characteristics, including total size of pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as an analysis of the overall regulatory burden.

Industry Developments

Focus on government healthcare reforms, epidemiological trends, company M&As, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

BMI Industry Forecasts

Forecasts to end-2018 for all key industry indicators (see list below) supported by explicit assumptions, plus analysis of key downside risks to the main forecast, including:

Healthcare: Total healthcare expenditure (US$bn), healthcare expenditure (% of GDP), healthcare expenditure per capita (US$), hospital beds (per `000 population), doctors (per `000 population), birth and mortality rate (per `000 population)

Pharmaceutical market: Drug expenditure (US$bn), drug expenditure (% of GDP), drug expenditure per capita (US$)

Patented drug market: Prescription drug sales (US$bn), prescription sales (% of total sales), sales broken down by 14 therapeutic areas (cardiovascular, anti-infectives etc.)

Generic drug market: Generic product sales (US$bn), generic sales (% of total sales)

OTC drug market: OTC sales (US$bn), OTC sales (% of total sales), sales broken down by product types (analgesics, skin treatments, vitamins and minerals etc.)

Medical Devices: Medical device sales (US$bn), medical device sales (% of total healthcare market)

Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against US$, government expenditure, external debt.

Competitive Landscape

The competitive landscape section provides comparative company analyses and rankings by US$ sales and % share of total sales - for the total pharmaceutical sector, as well as the OTC, generics, and distribution sub-sectors.

Company Profiles

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI's industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

secure
Benefit from discounts when you add multiple products to your basket
2 Products SAVE 10%
3 Products SAVE 15%
4 Products SAVE 20%
5 Products SAVE 25%
6 Products SAVE 30%
7 - 20 Products SAVE 35%
21 Products or more SAVE 40%

Testimonials

'An essential, multi-faceted research tool. BMI’s thorough understanding of the major market players enables an informed – and informative – review of the sector’s actual performance, together with useful insights into current industry issues, which are topped-off with detailed and invaluable forecasts of industry and macroeconomic trends.’

Senior Research Analyst, ABC International Bank plc